Estrella Immunopharma completes second dose cohort in EB103 trial; 100% CR rate

Estrella Immunopharma, Inc.

100% complete response (CR) rate at Month 1 in all evaluable patients in second dose cohort of STARLIGHT-1 trial.
All patients are high-risk, including one with CNS lymphoma; no treatment-related serious adverse events reported.
DSMB will review cumulative data to determine Recommended Phase II Dose (RP2D) for expansion phase.
EB103 is a CD19-redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell Non-Hodgkin's Lymphoma (NHL).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.